What is Summit Therapeutics's cost or amortized cost?

Summit Therapeutics (SMMT) reported cost or amortized cost of $590.5M in Q1 2026.

How has Summit Therapeutics's cost or amortized cost changed year-over-year?

Summit Therapeutics's cost or amortized cost increased by 67.0% year-over-year, from $353.66M to $590.5M.

What is the long-term trend for Summit Therapeutics's cost or amortized cost?

Over 2 years (2023 to 2025), Summit Therapeutics's cost or amortized cost has grown at a 146.4% compound annual growth rate (CAGR), from $114.78M to $696.91M.

Summit Therapeutics SMMT Cost or Amortized Cost

Cost or Amortized Cost at other companies

M&T BankMTB

$37.34B+9.3%

KKR & Co.KKR

$94.1B+9.2%

Ares CapitalARCC

$29.3B—

BKBK

$107.65B+9.8%

Bank of AmericaBAC

$903.7B-4.1%

PopularBPOP

——

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's cost or amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's cost or amortized cost?: Summit Therapeutics (SMMT) reported cost or amortized cost of $590.5M in Q1 2026.
How has Summit Therapeutics's cost or amortized cost changed year-over-year?: Summit Therapeutics's cost or amortized cost increased by 67.0% year-over-year, from $353.66M to $590.5M.
What is the long-term trend for Summit Therapeutics's cost or amortized cost?: Over 2 years (2023 to 2025), Summit Therapeutics's cost or amortized cost has grown at a 146.4% compound annual growth rate (CAGR), from $114.78M to $696.91M.